Replies to post #447566 on NorthWest Biotherapeutics Inc (NWBO)

[sukus]

Great info! Thanks Bright Boy!

[marzan]

wow it is such a strong authenticate statement! I am glad my money invested here is quite safe!

[Red_Right_Hand]

Interesting. That would seem to be the first public statement by the company regarding efficacy from the unblinded data. So why can't we get something more formal, like something in an 8k?

[newman2021]

may be MHRA approval and NICE pricing are already on its way; otherwise LP being a lawyer won't go this far: effective and safe and cheap.

[Nick119]

This aligns with the other post shared with the journalist who wrote the article as well, sharing that they are indeed a direct quote: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168049071

[Red_Right_Hand]

Can someone get Bigger to tweet this update out? This article was published during the trading day Friday.

[br8k0ut]

Appreciate you

[Dr Bala]

Decent.

[LearningEveryTrade]

A tad Mis-leading from DI .. or poster

The phrase "treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both North America and Europe” Attributed to recent LPOW UK interviews, well... see nwbio.com press release "about Northwest Biotherapeutics"

You will see this... (I only went back to 05/12/2021 PR)

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both North America and Europe. The Company has a broad platform technology for DCVax® dendritic cell-based vaccines. The Company’s lead program is a 331-patient Phase III trial of DCVax®-L for newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an “orphan disease.” This Phase III trial is now completed, with the trial data now being analyzed. The Company is also pursuing development of DCVax®-Direct for inoperable solid tumor cancers. It has completed a 40-patient Phase I trial and, as resources permit, is preparing for Phase II trials. The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania.

[HappyLibrarian]

Couldn’t a halfway competent webmaster just link to the article in a NWBO in the News section of the NWBO website?

That would allow NWBO to give their endorsement to the veracity of the quote to all shareholders at the same time without filtering through bulletin boards.

A crazy thought, I know.